Dermatology News and Research

Latest Dermatology News and Research

India's most-renowned homeopath receives Padma Shri award

Dr. Mukesh Batra, India's most-renowned homeopath, was conferred with the Padma Shri today, the country's fourth highest civilian award, by the President, Smt. Pratibha Patel for his exceptional and distinguished service in the field of medicine.

23 Apr 2012

More than 19,300 people participated at AAD’s 70th Annual Meeting

The American Academy of Dermatology's 70th Annual Meeting, recently held in San Diego from March 16-20, had a record attendance of more than 19,300 people from more than 102 countries.

17 Apr 2012

Vanda acquires license from Lilly to develop and commercialize NK-1R antagonist

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that it has acquired an exclusive world-wide license from Eli Lilly and Company (Lilly) to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

17 Apr 2012

Toxic nail varnish at salons raises concerns

It has been long seen that workers at nail salons suffer health problems. Workers have more headaches, respiratory problems and skin irritations than the general population and are exposed to chemicals at higher than recommended levels, according to research in scientific journals.

12 Apr 2012

Valeant acquires Pedinol Pharmacal

Valeant Pharmaceuticals International, Inc. announced today that Valeant has acquired Pedinol Pharmacal, Inc., a podiatry-focused, privately-owned specialty pharmaceutical company based in the U.S., for less than 1.5 times sales.

12 Apr 2012

Provectus announces data from PV-10 Phase 2 study on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.

10 Apr 2012

Lee's Pharma licenses rights to commercialize PL2200 Aspirin in China

PLx Pharma Inc, a Houston based pharmaceutical company developing gastrointestinal (GI) safer drugs has licensed to Lee's Pharmaceutical Holdings Limited (Lee's Pharma) the rights to register and commercialize in China, Hong Kong and Macau the PL2200 Aspirin, a GI safer aspirin product currently in development in the US, for prevention of cardiovascular diseases. Cardiovascular is one of the focus areas of Lee's Pharma.

10 Apr 2012

Internet-savvy consumers are incessant shoppers of health care providers and information

Today's Internet-savvy consumers are incessant shoppers of both health care providers and health care information, typically passing through four phases of online evaluation and connection with physicians, medical practices and other patients, according to Ron Harman King, a veteran digital marketer of specialty practices.

7 Apr 2012

Electronic pathology report more accurately identifies nonmelanoma skin cancer

Henry Ford Hospital dermatology researchers are urging caution about using claims data for identifying nonmelanoma skin cancer, suggesting that the commonly used method, which previously had not been validated, may be unreliable.

6 Apr 2012

Melanoma on the rise especially amongst the young

Women under 40 are hit hardest by the escalating incidence of melanoma, according to a Mayo Clinic study published in the April issue of Mayo Clinic Proceedings, out today. Researchers examined records from a decades-long database of all patient care in Olmsted County, Minn., and looked for first-time diagnoses of melanoma in patients 18-39 from 1970 to 2009. Melanoma cases increased eightfold among women in that time and fourfold for men, the authors say. However, death rates from melanoma fell during the same period, suggesting that early interventions may be helping to save some lives, said the researchers.

2 Apr 2012

Special fatty molecules pave novel way to treat infections, autoimmune diseases, allergies and cancer

An international research team led by scientists from Singapore Immunology Network (SIgN) under the Agency of Science, Technology and Research (A*STAR) discovered that a special class of fatty molecules is essential for activating a unique group of early-responding immune cells.

2 Apr 2012

Therakos introduces Lighting Up Lives campaign for patients with immune diseases

Therakos, Inc., a pioneer in the development of an innovative immune modulation therapy called extracorporeal photopheresis (ECP), today launched Lighting Up Lives, a 25-year anniversary campaign and year-long global initiative that honours the lives of patients with serious immune diseases impacted by ECP, as well as the healthcare professionals, caregivers and treatment centres that support them every step of the way.

2 Apr 2012

MEK1 mutation does not necessarily make BRAF mutant melanomas resistant to inhibitors

A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true.

2 Apr 2012

Online virtual communities may effectively train patients in mind/body techniques

A small study from Massachusetts General Hospital (MGH) researchers found that online virtual communities may be an effective way to train patients in meditation and other mind/body techniques. The ability to learn and practice approaches that elicit the relaxation response - a state of deep rest that has been shown to alleviate stress-related symptoms - in a virtual environment could help surmount several barriers that can restrict participation.

31 Mar 2012

XRCC2 gene mutations cause increased breast cancer risk

Mutations in a gene called XRCC2 cause increased breast cancer risk, according to a study published today in the American Journal of Human Genetics. The study looked at families that have a history of the disease but do not have mutations in the currently known breast cancer susceptibility genes.

30 Mar 2012

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.

29 Mar 2012

Sun damage revealed by UV photographs show skin cancer risk

Look at a middle school assembly - during their lifetime one in 50 of these kids will develop melanoma, the most serious form of skin cancer that kills 48,000 people every year, worldwide. Now look at these kids again - which are at highest risk? You can't tell, but a study recently published in the Journal of the American Academy of Dermatology shows that UV photography might provide important information about risk, not visible to the naked eye.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012